Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Проблемы аутоиммунитета в ревматологии
Проблемы аутоиммунитета в ревматологии
Насонов Е.Л. Проблемы аутоиммунитета в ревматологии. Терапевтический архив. 2023;95(12):1056–1063. DOI: 10.26442/00403660.2023.12.202501
© ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.
2023;95(12):1056–1063. DOI: 10.26442/00403660.2023.12.202501
© ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.
________________________________________________
2023;95(12):1056–1063. DOI: 10.26442/00403660.2023.12.202501
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Аутоиммунитет и аутовоспаления, взаимопотенциирующие патологические процессы, их развитие рассматривают в рамках «иммуновоспалительного» континуума (непрерывность при многообразии элементов), отражающего тесную взаимосвязь между врожденным и приобретенным типами иммунного ответа. Аутоиммунитет – ведущий механизм патогенеза большой группы хронических воспалительных заболеваний человека, определяющихся как аутоиммунные болезни, частота которых в популяции превышает 10%. Достижения молекулярной биологии, фармакогенетики и биоинформатики создали предпосылки для индивидуализации терапии системных аутоиммунных ревматических заболеваний в рамках концепции «персонифицированной» (personalized) медицины. Изучение механизмов иммунопатогенеза, совершенствование диагностики, расшифровка природы молекулярной таксономии, разработка подходов к профилактике и персонифицированной терапии системных аутоиммунных ревматических заболеваний относятся к числу приоритетных направлений медицины ХХ в.
Ключевые слова: аутоиммунитет, системные аутоиммунные ревматические болезни, аутовоспаление, аутоантитела, генно-инженерные биологические препараты
Keywords: autoimmunity, systemic autoimmune rheumatic diseases, autoinflammation, autoantibodies, genetically engineered biological agents
Ключевые слова: аутоиммунитет, системные аутоиммунные ревматические болезни, аутовоспаление, аутоантитела, генно-инженерные биологические препараты
________________________________________________
Keywords: autoimmunity, systemic autoimmune rheumatic diseases, autoinflammation, autoantibodies, genetically engineered biological agents
Полный текст
Список литературы
1. Furman D, Campisi J, Verdin E, et al. Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019;25(12):1822-32. DOI:10.1038/s41591-019-0675-0
2. McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med. 2006;3(8):e297. DOI:10.1371/journal.pmed.0030297
3. Szekanecz Z, McInnes IB, Schett G, et al. Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases. Nat Rev Rheumatol. 2021;17(10):585-95. DOI:10.1038/s41584-021-00652-9
4. Kerner G, Neehus AL, Philippot Q, et al. Genetic adaptation to pathogens and increased risk of inflammatory disorders in post-Neolithic Europe. Cell Genom. 2023;3(2):100248. DOI:10.1016/j.xgen.2022.100248
5. Насонов Е.Л. Современная концепция аутоиммунитета в ревматологии. Научно-практическая ревматология. 2023;61(4):397-420 [Nasonov EL. Modern concept of autoimmunity in rheumatology. Rheumatology Science and Practice. 2023;61(4):397-420 (in Russian)]. DOI:10.47360/1995-4484-2023-397-420
6. Bluestone JA. Mechanisms of tolerance. Immunol Rev. 2011;24(1):5-19. DOI:10.1111/j.1600-065X.2011.01019.x
7. Rosenblum MD, Remedios KA, Abbas AK. Mechanisms of human autoimmunity. J Clin Invest. 2015;125(6):2228-33. DOI:10.1172/JCI78088
8. Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015;278(4):369-95. DOI:10.1111/joim.12395
9. Pisetsky DS. Pathogenesis of autoimmune disease. Nat Rev Nephrol. 2023:1-16. DOI:10.1038/s41581-023-00720-1
10. McGonagle D, Aydin SZ, Gül A, et al. 'MHC-I-opathy'-unified concept for spondyloarthritis and Behçet disease. Nat Rev Rheumatol. 2015;11(12):731-40. DOI:10.1038/nrrheum.2015.147
11. Насонов Е.Л., Авдеева А.С., Дибров Д.А. Ревматоидный артрит как клинико-иммунологический синдром: фокус на серонегативный субтип заболевания. Научно-практическая ревматология. 2023;61(3):276-91 [Nasonov EL, Avdeeva AS, Dibrov DA. Rheumatoid arthritis as a clinical and immunological syndrome: focus on the seronegative subtype of the disease. Rheumatology Science and Practice. 2023;61(3):276-91 (in Russian)]. DOI:10.47360/1995-4484-2023-276-291
12. Lenti MV, Rossi CM, Melazzini F, et al. Seronegative autoimmune diseases: A challenging diagnosis. Autoimmun Rev. 2022;21(9):103143. DOI:10.1016/j.autrev.2022.103143
13. Schett G, McInnes IB, Neurath MF. Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs. N Engl J Med. 2021;385(7):628-39. DOI:10.1056/NEJMra1909094
14. van Wesemael TJ, Huizinga TWJ, Toes REM, an der Woude D. From phenotype to pathophysiology – placing rheumatic diseases in an immunological perspective. Lancet Rheumatol. 2022. DOI:10.1016/S2665-9913(21)00369-6
15. Bieber K, Hundt JE, Yu X, et al. Autoimmune pre-disease. Autoimmun Rev. 2023;22(2):103236. DOI:10.1016/j.autrev.2022.103236
16. Насонов Е.Л. Проблемы иммунопатологии ревматоидного артрита: эволюция болезни. Научно-практическая ревматология. 2017;55(3):277-94 [Nasonov EL. Problems of rheumatoid arthritis immunopathology: evolution of the disease. Rheumatology Science and Practice. 2017;55(3):277-94 (in Russian)]. DOI:10.14412/1995-4484-2017-277-294
17. Насонов Е.Л., Попкова Т.В., Панафидина Т.А. Проблемы ранней системной красной волчанки в период пандемии COVID-19. Научно-практическая ревматология. 2021;59(2):119-28 [Nasonov EL, Popkova TV, Panafidina TA. Problems of early diagnosis of systemic lupus erythematosus during the COVID-19 pandemic. Rheumatology Science and Practice. 2021;59(2):119-28 (in Russian)]. DOI:10.47360/1995-4484-2021-119-128
18. Rojas M, Ramírez-Santana C, Acosta-Ampudia Y, et al. New insights into the taxonomy of autoimmune diseases based on polyautoimmunity. J Autoimmun. 2022;126:102780. DOI:10.1016/j.jaut.2021.102780
19. Miller FW. The increasing prevalence of autoimmunity and autoimmune diseases: an urgent call to action for improved understanding, diagnosis, treatment, and prevention. Curr Opin Immunol. 2023;80:102266. DOI:10.1016/j.coi.2022.102266
20. Conrad N, Misra S, Verbakel JY, et al. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet. 2023;401(10391):1878-90. DOI:10.1016/S0140-6736(23)00457-9
21. David T, Ling SF, Barton A. Genetics of immune-mediated inflammatory diseases. Clin Exp Immunol. 2018;193(1):3-12. DOI:10.1111/cei.13101
22. Cutolo M, Straub RH. Sex steroids and autoimmune rheumatic diseases: state of the art. Nat Rev Rheumatol. 2020;16(11):628-44. DOI:10.1038/s41584-020-0503-4
23. Sundaresan B, Shirafkan F, Ripperger K, Rattay K. The Role of Viral Infections in the Onset of Autoimmune Diseases. Viruses. 2023;15(3):782. DOI:10.3390/v15030782
24. Hahn J, Cool NR, Alexander EK, et al. Vitamin d and marine 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial. BMJ. 2022;376:e066452/bmj-2021-066452. DOI:10.1136/bmj-2021-066452
25. Shaheen WA, Quraishi MN, Iqbal TH. Gut microbiome and autoimmune disorders. Clin Exp Immunol. 2022;209(2):161-74. DOI:10.1093/cei/uxac057
26. Chaturvedi S, Braunstein EM, Brodsky RA. Antiphospholipid syndrome: Complement activation, complement gene mutations, and therapeutic implications. J Thromb Haemost. 2021;19(3):607-16. DOI:10.1111/jth.15082
27. Rubin SJS, Bloom MS, Robinson WH. B cell checkpoints in autoimmune rheumatic diseases. Nat Rev Rheumatol. 2019;15(5):303-15. DOI:10.1038/s41584-019-0211-0
28. Jenks SA, Cashman KS, Woodruff MC, et al. Extrafollicular responses in humans and SLE. Immunol Rev. 2019;288(1):136-48. DOI:10.1111/imr.12741
29. Насонов Е.Л., Попкова ТВ, Лила АМ. Белимумаб в лечении системной красной волчанки: 20 лет фундаментальных исследований, 10 лет клинической практики. Научно-практическая ревматология. 2021;59(4):367-83 [Nasonov EL, Popkova TV, Lila AM. Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice. Rheumatology Science and Practice. 2021;59(4):367-83 (in Russian)]. DOI:10.47360/1995-4484-2021-367-383
30. Annunziato F, Romagnani C, Romagnani S. The 3 major types of innate and adaptive cell-mediated effector immunity. J Allergy Clin Immunol. 2015;135(3):626-35. DOI:10.1016/j.jaci.2014.11.001
31. Воробьева Н.В., Черняк Б.В. НЕТоз: молекулярные механизмы, роль в физиологии и патологии. Биохимия. 2020;85:1383-97 [Vorobyova NV, Chernyak BV. NETosis: molecular mechanisms, role in physiology and pathology. Biochemistry. 2020;85:1383-97 (in Russian)]. DOI:10.31857/S0320972520100061
32. Wigerblad G, Kaplan MJ. Neutrophil extracellular traps in systemic autoimmune and autoinflammatory diseases. Nat Rev Immunol. 2023;23(5):274-88.
DOI:10.1038/s41577-022-00787-0
33. Насонов Е.Л., Авдеева А.С. Иммуновоспалительные ревматические заболевания, связанные с интерфероном типа I: новые данные. Научно-практическая ревматология. 2019;57(4):452-61 [Nasonov EL, Avdeeva AS. Immunoinflammatory rheumatic diseases associated with type i interferon: new evidence. Rheumatology Science and Practice. 2019;57(4):452-61 (in Russian)]. DOI:10.14412/1995-4484-2019-452-461
34. Насонов Е.Л., Авдеева А.С., Попкова Т.В. Новые возможности фармакотерапии системной красной волчанки: перспективы применения анифролумаба (моноклональные антитела к рецепторам интерферона типа I). Научно-практическая ревматология. 2021;59(5):537-46 [Nasonov EL, Avdeeva AS, Popkova TV. New possibilities of pharmacotherapy for systemic lupus erythematosus: Prospects for the use of anifrolumab (monoclonal antibodies to type I interferon receptor). Rheumatology Science and Practice. 2021;59(5):537-46 (in Russian)]. DOI:10.47360/1995-4484-2021-537-546
35. Suurmond J, Diamond B. Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity. J Clin Invest. 2015;125(6):2194-202. DOI:10.1172/JCI78084
36. Burbelo PD, Iadarola MJ, Keller JM, Warner BM. Autoantibodies Targeting Intracellular and Extracellular Proteins in Autoimmunity. Front Immunol. 2021;12:548469. DOI:10.3389/fimmu.2021.548469
37. Sokolova MV, Schett G, Steffen U. Autoantibodies in Rheumatoid Arthritis: Historical Background and Novel Findings. Clin Rev Allergy Immunol. 2022;63(2):138-51. DOI:10.1007/s12016-021-08890-1
38. Moritz CP, Paul S, Stoevesandt O, et al. Autoantigenomics: Holistic characterization of autoantigen repertoires for a better understanding of autoimmune diseases. Autoimmun Rev. 2020;19(2):102450. DOI:10.1016/j.autrev.2019.102450
39. Гордеев А.В., Галушко Е.А., Насонов Е.Л. Концепция мультиморбидности в ревматологической практике. Научно-практическая ревматология. 2014;52(4):362-5 [Gordeev AV, Galushko EA, Nasonov EL. The concept of multimorbidity in rheumatologic practice. Rheumatology Science and Practice. 2014;52(4):362-5 (in Russian)].
DOI:10.14412/1995-4484-2014-362-365
40. Roy P, Orecchioni M, Ley K. How the immune system shapes atherosclerosis: roles of innate and adaptive immunity. Nat Rev Immunol. 2022;22(4):251-65.
DOI:10.1038/s41577-021-00584-1
41. Насонов Е.Л. Коронавирусная болезнь 2019 (COVID-19): размышления ревматолога. Научно-практическая ревматология. 2020;58(2):123-32 [Nasonov EL. Coronavirus disease 2019 (COVID-19): A Rheumatologist’s thoughts. Rheumatology Science and Practice. 2020;58(2):123-32 (in Russian)]. DOI:10.14412/1995-4484-2020-123-132
42. Knight JS, Caricchio R, Casanova JL, et al. The intersection of COVID-19 and autoimmunity. J Clin Invest. 2021;131(24):e154886. DOI:10.1172/JCI154886
43. Насонов Е.Л., Бекетова Т.В., Решетняк Т.М., и др. Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные ревматические заболевания: на перекрестке проблем тромбовоспаления и аутоиммунитета. Научно-практическая ревматология. 2020;58(4):353-67 [Nasonov EL, Beketova TV, Reshetnyak TM, et al. Coronavirus disease 2019 (COVID-19) and immune-mediated inflammatory rheumatic diseases: at the crossroads of thromboinflammation and autoimmunity. Rheumatology Science and Practice. 2020;58(4):353-67 (in Russian)]. DOI:10.47360/1995-4484-2020-353-367
44. Nasonov EL, Samsonov MY, Lila AM. Coronavirus Infection 2019 (COVID-19) and Autoimmunity. Her Russ Acad Sci. 2022;92(4):398-403. DOI:10.1134/S1019331622040062
45. Chang R, Yen-Ting Chen T, Wang SI, et al. Risk of autoimmune diseases in patients with COVID-19: A retrospective cohort study. EClinicalMedicine. 2023;56:101783. DOI:10.1016/j.eclinm.2022.101783
46. Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175-87. DOI:10.1136/annrheumdis-2017-211555
47. Насонов Е.Л. Фармакотерапия ревматоидного артрита: новая стратегия, новые мишени. Научно-практическая ревматология. 2017;55(4):409-19 [Nasonov EL. Pharmacotherapy for rheumatoid arthritis: new strategy, new targets. Rheumatology Science and Practice. 2017;55(4):409-19 (in Russian)]. DOI:10.14412/1995-4484-2017-409-419
48. Насонов Е.Л., Бекетова Т.В., Ананьева Л.П., и др. Перспективы анти-В-клеточной терапии при иммуновоспалительных ревматических заболеваниях. Научно-практическая ревматология. 2019;57:1-40 [Nasonov EL, Beketova TV, Ananyeva LP, et al. Prospects for anti-B-cell therapy in immuno-inflammatory rheumatic diseases. Rheumatology Science and Practice. 2019;57:1-40 (in Russian)]. DOI:10.14412/1995-4484-2019-3-40
49. Orvain C, Boulch M, Bousso P, et al. Is there a place for chimeric antigen receptor-T cells in the treatment of chronic autoimmune rheumatic diseases? Arthritis Rheumatol. 2021;73(11):1954-65. DOI:10.1002/art.41812
50. Насонов Е.Л., Лила А.М. Ингибиторы Янус-киназ при иммуновоспалительных ревматических заболеваниях: новые возможности и перспективы. Научно-практическая ревматология. 2019;57(1):8-16 [Nasonov EL, Lila AM. Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: New opportunities and prospects. Rheumatology Science and Practice. 2019;57(1):8-16 (in Russian)]. DOI:10.14412/1995-4484-2019-8-16
51. Насонов Е.Л. Абатацепт при ревматоидном артрите: новая форма, новые механизмы, новые возможности. Научно-практическая ревматология. 2015;53(5):522-41 [Nasonov EL. Abatacept for rheumatoid arthritis: a novel formulation, new mechanisms, new possibilities. Rheumatology Science and Practice. 2015;53(5):522-41 (in Russian)]. DOI:10.14412/1995-4484-2015-522-541
52. Насонов Е.Л., Решетняк Т.М., Алекберова З.С. Тромботическая микроангиопатия в ревматологии: связь тромбовоспаления и аутоиммунитета. Терапевтический архив. 2020;92(5):4-14 [Nasonov EL, Reshetnyak TM, Alekberova ZS. Thrombotic microangiopathy in rheumatology: the relationship of thrombosis and autoimmunity. Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(5):4-14 (in Russian)]. DOI:10.26442/00403660.2020.05.000697
53. Насонов Е.Л., Лила А.М., Галушко Е.А., Амирджанова В.Н. Стратегия развития ревматологии: от научных достижений к практическому здравоохранению. Научно-практическая ревматология. 2017;55(4):339-43 [Nasonov EL, Lila AM, Galushko EA, Amirdzhanova VN. Strategy for development of rheumatology: from scientific achievements to practical healthcare. Rheumatology Science and Practice. 2017;55(4):339-43 (in Russian)]. DOI:10.14412/1995-4484-2017-339-343
54. Насонов Е.Л., Александрова Е.Н., Новиков А.А. Аутоиммунные ревматические заболевания – проблемы иммунопатологии и персонифицированной терапии. Вестник РАМН. 2015;70(2):169-82 [Nasonov EL, Aleksandrova EN, Novikov AA. Autoimmune Rheumatic Diseases – Problems of Immunopathology and Personalized Treatment. Vestnik RAMN. 2015;70(2):169-82 (in Russian)]. DOI:10.15690/vramn.v70i2.1310
55. Laigle L, Chadli L, Moingeon P. Biomarker-driven development of new therapies for autoimmune diseases: current status and future promises. Expert Rev Clin Immunol. 2023;19(3):305-14. DOI:10.1080/1744666X.2023.2172404
56. Felten R, Mertz P, Sebbag E, et al. Novel therapeutic strategies for autoimmune and inflammatory rheumatic diseases. Drug Discov Today. 2023;28(7):103612. DOI:10.1016/j.drudis.2023.1
2. McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med. 2006;3(8):e297. DOI:10.1371/journal.pmed.0030297
3. Szekanecz Z, McInnes IB, Schett G, et al. Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases. Nat Rev Rheumatol. 2021;17(10):585-95. DOI:10.1038/s41584-021-00652-9
4. Kerner G, Neehus AL, Philippot Q, et al. Genetic adaptation to pathogens and increased risk of inflammatory disorders in post-Neolithic Europe. Cell Genom. 2023;3(2):100248. DOI:10.1016/j.xgen.2022.100248
5. Nasonov EL. Modern concept of autoimmunity in rheumatology. Rheumatology Science and Practice. 2023;61(4):397-420 (in Russian). DOI:10.47360/1995-4484-2023-397-420
6. Bluestone JA. Mechanisms of tolerance. Immunol Rev. 2011;24(1):5-19. DOI:10.1111/j.1600-065X.2011.01019.x
7. Rosenblum MD, Remedios KA, Abbas AK. Mechanisms of human autoimmunity. J Clin Invest. 2015;125(6):2228-33. DOI:10.1172/JCI78088
8. Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015;278(4):369-95. DOI:10.1111/joim.12395
9. Pisetsky DS. Pathogenesis of autoimmune disease. Nat Rev Nephrol. 2023:1-16. DOI:10.1038/s41581-023-00720-1
10. McGonagle D, Aydin SZ, Gül A, et al. 'MHC-I-opathy'-unified concept for spondyloarthritis and Behçet disease. Nat Rev Rheumatol. 2015;11(12):731-40. DOI:10.1038/nrrheum.2015.147
11. Nasonov EL, Avdeeva AS, Dibrov DA. Rheumatoid arthritis as a clinical and immunological syndrome: focus on the seronegative subtype of the disease. Rheumatology Science and Practice. 2023;61(3):276-91 (in Russian). DOI:10.47360/1995-4484-2023-276-291
12. Lenti MV, Rossi CM, Melazzini F, et al. Seronegative autoimmune diseases: A challenging diagnosis. Autoimmun Rev. 2022;21(9):103143. DOI:10.1016/j.autrev.2022.103143
13. Schett G, McInnes IB, Neurath MF. Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs. N Engl J Med. 2021;385(7):628-39. DOI:10.1056/NEJMra1909094
14. van Wesemael TJ, Huizinga TWJ, Toes REM, an der Woude D. From phenotype to pathophysiology – placing rheumatic diseases in an immunological perspective. Lancet Rheumatol. 2022. DOI:10.1016/S2665-9913(21)00369-6
15. Bieber K, Hundt JE, Yu X, et al. Autoimmune pre-disease. Autoimmun Rev. 2023;22(2):103236. DOI:10.1016/j.autrev.2022.103236
16. Nasonov EL. Problems of rheumatoid arthritis immunopathology: evolution of the disease. Rheumatology Science and Practice. 2017;55(3):277-94 (in Russian).
DOI:10.14412/1995-4484-2017-277-294
17. Nasonov EL, Popkova TV, Panafidina TA. Problems of early diagnosis of systemic lupus erythematosus during the COVID-19 pandemic. Rheumatology Science and Practice. 2021;59(2):119-28 (in Russian). DOI:10.47360/1995-4484-2021-119-128
18. Rojas M, Ramírez-Santana C, Acosta-Ampudia Y, et al. New insights into the taxonomy of autoimmune diseases based on polyautoimmunity. J Autoimmun. 2022;126:102780. DOI:10.1016/j.jaut.2021.102780
19. Miller FW. The increasing prevalence of autoimmunity and autoimmune diseases: an urgent call to action for improved understanding, diagnosis, treatment, and prevention. Curr Opin Immunol. 2023;80:102266. DOI:10.1016/j.coi.2022.102266
20. Conrad N, Misra S, Verbakel JY, et al. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet. 2023;401(10391):1878-90. DOI:10.1016/S0140-6736(23)00457-9
21. David T, Ling SF, Barton A. Genetics of immune-mediated inflammatory diseases. Clin Exp Immunol. 2018;193(1):3-12. DOI:10.1111/cei.13101
22. Cutolo M, Straub RH. Sex steroids and autoimmune rheumatic diseases: state of the art. Nat Rev Rheumatol. 2020;16(11):628-44. DOI:10.1038/s41584-020-0503-4
23. Sundaresan B, Shirafkan F, Ripperger K, Rattay K. The Role of Viral Infections in the Onset of Autoimmune Diseases. Viruses. 2023;15(3):782. DOI:10.3390/v15030782
24. Hahn J, Cool NR, Alexander EK, et al. Vitamin d and marine 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial. BMJ. 2022;376:e066452/bmj-2021-066452. DOI:10.1136/bmj-2021-066452
25. Shaheen WA, Quraishi MN, Iqbal TH. Gut microbiome and autoimmune disorders. Clin Exp Immunol. 2022;209(2):161-74. DOI:10.1093/cei/uxac057
26. Chaturvedi S, Braunstein EM, Brodsky RA. Antiphospholipid syndrome: Complement activation, complement gene mutations, and therapeutic implications. J Thromb Haemost. 2021;19(3):607-16. DOI:10.1111/jth.15082
27. Rubin SJS, Bloom MS, Robinson WH. B cell checkpoints in autoimmune rheumatic diseases. Nat Rev Rheumatol. 2019;15(5):303-15. DOI:10.1038/s41584-019-0211-0
28. Jenks SA, Cashman KS, Woodruff MC, et al. Extrafollicular responses in humans and SLE. Immunol Rev. 2019;288(1):136-48. DOI:10.1111/imr.12741
29. Nasonov EL, Popkova TV, Lila AM. Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice. Rheumatology Science and Practice. 2021;59(4):367-83 (in Russian). DOI:10.47360/1995-4484-2021-367-383
30. Annunziato F, Romagnani C, Romagnani S. The 3 major types of innate and adaptive cell-mediated effector immunity. J Allergy Clin Immunol. 2015;135(3):626-35. DOI:10.1016/j.jaci.2014.11.001
31. Vorobyova NV, Chernyak BV. NETosis: molecular mechanisms, role in physiology and pathology. Biochemistry. 2020;85:1383-97 (in Russian). DOI:10.31857/S0320972520100061
32. Wigerblad G, Kaplan MJ. Neutrophil extracellular traps in systemic autoimmune and autoinflammatory diseases. Nat Rev Immunol. 2023;23(5):274-88.
DOI:10.1038/s41577-022-00787-0
33. Nasonov EL, Avdeeva AS. Immunoinflammatory rheumatic diseases associated with type i interferon: new evidence. Rheumatology Science and Practice. 2019;57(4):452-61 (in Russian). DOI:10.14412/1995-4484-2019-452-461
34. Nasonov EL, Avdeeva AS, Popkova TV. New possibilities of pharmacotherapy for systemic lupus erythematosus: Prospects for the use of anifrolumab (monoclonal antibodies to type I interferon receptor). Rheumatology Science and Practice. 2021;59(5):537-46 (in Russian). DOI:10.47360/1995-4484-2021-537-546
35. Suurmond J, Diamond B. Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity. J Clin Invest. 2015;125(6):2194-202. DOI:10.1172/JCI78084
36. Burbelo PD, Iadarola MJ, Keller JM, Warner BM. Autoantibodies Targeting Intracellular and Extracellular Proteins in Autoimmunity. Front Immunol. 2021;12:548469. DOI:10.3389/fimmu.2021.548469
37. Sokolova MV, Schett G, Steffen U. Autoantibodies in Rheumatoid Arthritis: Historical Background and Novel Findings. Clin Rev Allergy Immunol. 2022;63(2):138-51. DOI:10.1007/s12016-021-08890-1
38. Moritz CP, Paul S, Stoevesandt O, et al. Autoantigenomics: Holistic characterization of autoantigen repertoires for a better understanding of autoimmune diseases. Autoimmun Rev. 2020;19(2):102450. DOI:10.1016/j.autrev.2019.102450
39. Gordeev AV, Galushko EA, Nasonov EL. The concept of multimorbidity in rheumatologic practice. Rheumatology Science and Practice. 2014;52(4):362-5 (in Russian). DOI:10.14412/1995-4484-2014-362-365
40. Roy P, Orecchioni M, Ley K. How the immune system shapes atherosclerosis: roles of innate and adaptive immunity. Nat Rev Immunol. 2022;22(4):251-65.
DOI:10.1038/s41577-021-00584-1
41. Nasonov EL. Coronavirus disease 2019 (COVID-19): A Rheumatologist’s thoughts. Rheumatology Science and Practice. 2020;58(2):123-32 (in Russian).
DOI:10.14412/1995-4484-2020-123-132
42. Knight JS, Caricchio R, Casanova JL, et al. The intersection of COVID-19 and autoimmunity. J Clin Invest. 2021;131(24):e154886. DOI:10.1172/JCI154886
43. Nasonov EL, Beketova TV, Reshetnyak TM, et al. Coronavirus disease 2019 (COVID-19) and immune-mediated inflammatory rheumatic diseases: at the crossroads of thromboinflammation and autoimmunity. Rheumatology Science and Practice. 2020;58(4):353-67 (in Russian). DOI:10.47360/1995-4484-2020-353-367
44. Nasonov EL, Samsonov MY, Lila AM. Coronavirus Infection 2019 (COVID-19) and Autoimmunity. Her Russ Acad Sci. 2022;92(4):398-403. DOI:10.1134/S1019331622040062
45. Chang R, Yen-Ting Chen T, Wang SI, et al. Risk of autoimmune diseases in patients with COVID-19: A retrospective cohort study. EClinicalMedicine. 2023;56:101783. DOI:10.1016/j.eclinm.2022.101783
46. Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175-87. DOI:10.1136/annrheumdis-2017-211555
47. Nasonov EL. Pharmacotherapy for rheumatoid arthritis: new strategy, new targets. Rheumatology Science and Practice. 2017;55(4):409-19 (in Russian).
DOI:10.14412/1995-4484-2017-409-419
48. Nasonov EL, Beketova TV, Ananyeva LP, et al. Prospects for anti-B-cell therapy in immuno-inflammatory rheumatic diseases. Rheumatology Science and Practice. 2019;57:1-40 (in Russian). DOI:10.14412/1995-4484-2019-3-40
49. Orvain C, Boulch M, Bousso P, et al. Is there a place for chimeric antigen receptor-T cells in the treatment of chronic autoimmune rheumatic diseases? Arthritis Rheumatol. 2021;73(11):1954-65. DOI:10.1002/art.41812
50. Nasonov EL, Lila AM. Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: New opportunities and prospects. Rheumatology Science and Practice. 2019;57(1):8-16 (in Russian). DOI:10.14412/1995-4484-2019-8-16
51. Nasonov EL. Abatacept for rheumatoid arthritis: a novel formulation, new mechanisms, new possibilities. Rheumatology Science and Practice. 2015;53(5):522-41 (in Russian). DOI:10.14412/1995-4484-2015-522-541
52. Nasonov EL, Reshetnyak TM, Alekberova ZS. Thrombotic microangiopathy in rheumatology: the relationship of thrombosis and autoimmunity. Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(5):4-14 (in Russian). DOI:10.26442/00403660.2020.05.000697
53. Nasonov EL, Lila AM, Galushko EA, Amirdzhanova VN. Strategy for development of rheumatology: from scientific achievements to practical healthcare. Rheumatology Science and Practice. 2017;55(4):339-43 (in Russian). DOI:10.14412/1995-4484-2017-339-343
54. Nasonov EL, Aleksandrova EN, Novikov AA. Autoimmune Rheumatic Diseases – Problems of Immunopathology and Personalized Treatment. Vestnik RAMN. 2015;70(2):169-82 (in Russian). DOI:10.15690/vramn.v70i2.1310
55. Laigle L, Chadli L, Moingeon P. Biomarker-driven development of new therapies for autoimmune diseases: current status and future promises. Expert Rev Clin Immunol. 2023;19(3):305-14. DOI:10.1080/1744666X.2023.2172404
56. Felten R, Mertz P, Sebbag E, et al. Novel therapeutic strategies for autoimmune and inflammatory rheumatic diseases. Drug Discov Today. 2023;28(7):103612. DOI:10.1016/j.drudis.2023.1
2. McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med. 2006;3(8):e297. DOI:10.1371/journal.pmed.0030297
3. Szekanecz Z, McInnes IB, Schett G, et al. Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases. Nat Rev Rheumatol. 2021;17(10):585-95. DOI:10.1038/s41584-021-00652-9
4. Kerner G, Neehus AL, Philippot Q, et al. Genetic adaptation to pathogens and increased risk of inflammatory disorders in post-Neolithic Europe. Cell Genom. 2023;3(2):100248. DOI:10.1016/j.xgen.2022.100248
5. Насонов Е.Л. Современная концепция аутоиммунитета в ревматологии. Научно-практическая ревматология. 2023;61(4):397-420 [Nasonov EL. Modern concept of autoimmunity in rheumatology. Rheumatology Science and Practice. 2023;61(4):397-420 (in Russian)]. DOI:10.47360/1995-4484-2023-397-420
6. Bluestone JA. Mechanisms of tolerance. Immunol Rev. 2011;24(1):5-19. DOI:10.1111/j.1600-065X.2011.01019.x
7. Rosenblum MD, Remedios KA, Abbas AK. Mechanisms of human autoimmunity. J Clin Invest. 2015;125(6):2228-33. DOI:10.1172/JCI78088
8. Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015;278(4):369-95. DOI:10.1111/joim.12395
9. Pisetsky DS. Pathogenesis of autoimmune disease. Nat Rev Nephrol. 2023:1-16. DOI:10.1038/s41581-023-00720-1
10. McGonagle D, Aydin SZ, Gül A, et al. 'MHC-I-opathy'-unified concept for spondyloarthritis and Behçet disease. Nat Rev Rheumatol. 2015;11(12):731-40. DOI:10.1038/nrrheum.2015.147
11. Насонов Е.Л., Авдеева А.С., Дибров Д.А. Ревматоидный артрит как клинико-иммунологический синдром: фокус на серонегативный субтип заболевания. Научно-практическая ревматология. 2023;61(3):276-91 [Nasonov EL, Avdeeva AS, Dibrov DA. Rheumatoid arthritis as a clinical and immunological syndrome: focus on the seronegative subtype of the disease. Rheumatology Science and Practice. 2023;61(3):276-91 (in Russian)]. DOI:10.47360/1995-4484-2023-276-291
12. Lenti MV, Rossi CM, Melazzini F, et al. Seronegative autoimmune diseases: A challenging diagnosis. Autoimmun Rev. 2022;21(9):103143. DOI:10.1016/j.autrev.2022.103143
13. Schett G, McInnes IB, Neurath MF. Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs. N Engl J Med. 2021;385(7):628-39. DOI:10.1056/NEJMra1909094
14. van Wesemael TJ, Huizinga TWJ, Toes REM, an der Woude D. From phenotype to pathophysiology – placing rheumatic diseases in an immunological perspective. Lancet Rheumatol. 2022. DOI:10.1016/S2665-9913(21)00369-6
15. Bieber K, Hundt JE, Yu X, et al. Autoimmune pre-disease. Autoimmun Rev. 2023;22(2):103236. DOI:10.1016/j.autrev.2022.103236
16. Насонов Е.Л. Проблемы иммунопатологии ревматоидного артрита: эволюция болезни. Научно-практическая ревматология. 2017;55(3):277-94 [Nasonov EL. Problems of rheumatoid arthritis immunopathology: evolution of the disease. Rheumatology Science and Practice. 2017;55(3):277-94 (in Russian)]. DOI:10.14412/1995-4484-2017-277-294
17. Насонов Е.Л., Попкова Т.В., Панафидина Т.А. Проблемы ранней системной красной волчанки в период пандемии COVID-19. Научно-практическая ревматология. 2021;59(2):119-28 [Nasonov EL, Popkova TV, Panafidina TA. Problems of early diagnosis of systemic lupus erythematosus during the COVID-19 pandemic. Rheumatology Science and Practice. 2021;59(2):119-28 (in Russian)]. DOI:10.47360/1995-4484-2021-119-128
18. Rojas M, Ramírez-Santana C, Acosta-Ampudia Y, et al. New insights into the taxonomy of autoimmune diseases based on polyautoimmunity. J Autoimmun. 2022;126:102780. DOI:10.1016/j.jaut.2021.102780
19. Miller FW. The increasing prevalence of autoimmunity and autoimmune diseases: an urgent call to action for improved understanding, diagnosis, treatment, and prevention. Curr Opin Immunol. 2023;80:102266. DOI:10.1016/j.coi.2022.102266
20. Conrad N, Misra S, Verbakel JY, et al. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet. 2023;401(10391):1878-90. DOI:10.1016/S0140-6736(23)00457-9
21. David T, Ling SF, Barton A. Genetics of immune-mediated inflammatory diseases. Clin Exp Immunol. 2018;193(1):3-12. DOI:10.1111/cei.13101
22. Cutolo M, Straub RH. Sex steroids and autoimmune rheumatic diseases: state of the art. Nat Rev Rheumatol. 2020;16(11):628-44. DOI:10.1038/s41584-020-0503-4
23. Sundaresan B, Shirafkan F, Ripperger K, Rattay K. The Role of Viral Infections in the Onset of Autoimmune Diseases. Viruses. 2023;15(3):782. DOI:10.3390/v15030782
24. Hahn J, Cool NR, Alexander EK, et al. Vitamin d and marine 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial. BMJ. 2022;376:e066452/bmj-2021-066452. DOI:10.1136/bmj-2021-066452
25. Shaheen WA, Quraishi MN, Iqbal TH. Gut microbiome and autoimmune disorders. Clin Exp Immunol. 2022;209(2):161-74. DOI:10.1093/cei/uxac057
26. Chaturvedi S, Braunstein EM, Brodsky RA. Antiphospholipid syndrome: Complement activation, complement gene mutations, and therapeutic implications. J Thromb Haemost. 2021;19(3):607-16. DOI:10.1111/jth.15082
27. Rubin SJS, Bloom MS, Robinson WH. B cell checkpoints in autoimmune rheumatic diseases. Nat Rev Rheumatol. 2019;15(5):303-15. DOI:10.1038/s41584-019-0211-0
28. Jenks SA, Cashman KS, Woodruff MC, et al. Extrafollicular responses in humans and SLE. Immunol Rev. 2019;288(1):136-48. DOI:10.1111/imr.12741
29. Насонов Е.Л., Попкова ТВ, Лила АМ. Белимумаб в лечении системной красной волчанки: 20 лет фундаментальных исследований, 10 лет клинической практики. Научно-практическая ревматология. 2021;59(4):367-83 [Nasonov EL, Popkova TV, Lila AM. Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice. Rheumatology Science and Practice. 2021;59(4):367-83 (in Russian)]. DOI:10.47360/1995-4484-2021-367-383
30. Annunziato F, Romagnani C, Romagnani S. The 3 major types of innate and adaptive cell-mediated effector immunity. J Allergy Clin Immunol. 2015;135(3):626-35. DOI:10.1016/j.jaci.2014.11.001
31. Воробьева Н.В., Черняк Б.В. НЕТоз: молекулярные механизмы, роль в физиологии и патологии. Биохимия. 2020;85:1383-97 [Vorobyova NV, Chernyak BV. NETosis: molecular mechanisms, role in physiology and pathology. Biochemistry. 2020;85:1383-97 (in Russian)]. DOI:10.31857/S0320972520100061
32. Wigerblad G, Kaplan MJ. Neutrophil extracellular traps in systemic autoimmune and autoinflammatory diseases. Nat Rev Immunol. 2023;23(5):274-88.
DOI:10.1038/s41577-022-00787-0
33. Насонов Е.Л., Авдеева А.С. Иммуновоспалительные ревматические заболевания, связанные с интерфероном типа I: новые данные. Научно-практическая ревматология. 2019;57(4):452-61 [Nasonov EL, Avdeeva AS. Immunoinflammatory rheumatic diseases associated with type i interferon: new evidence. Rheumatology Science and Practice. 2019;57(4):452-61 (in Russian)]. DOI:10.14412/1995-4484-2019-452-461
34. Насонов Е.Л., Авдеева А.С., Попкова Т.В. Новые возможности фармакотерапии системной красной волчанки: перспективы применения анифролумаба (моноклональные антитела к рецепторам интерферона типа I). Научно-практическая ревматология. 2021;59(5):537-46 [Nasonov EL, Avdeeva AS, Popkova TV. New possibilities of pharmacotherapy for systemic lupus erythematosus: Prospects for the use of anifrolumab (monoclonal antibodies to type I interferon receptor). Rheumatology Science and Practice. 2021;59(5):537-46 (in Russian)]. DOI:10.47360/1995-4484-2021-537-546
35. Suurmond J, Diamond B. Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity. J Clin Invest. 2015;125(6):2194-202. DOI:10.1172/JCI78084
36. Burbelo PD, Iadarola MJ, Keller JM, Warner BM. Autoantibodies Targeting Intracellular and Extracellular Proteins in Autoimmunity. Front Immunol. 2021;12:548469. DOI:10.3389/fimmu.2021.548469
37. Sokolova MV, Schett G, Steffen U. Autoantibodies in Rheumatoid Arthritis: Historical Background and Novel Findings. Clin Rev Allergy Immunol. 2022;63(2):138-51. DOI:10.1007/s12016-021-08890-1
38. Moritz CP, Paul S, Stoevesandt O, et al. Autoantigenomics: Holistic characterization of autoantigen repertoires for a better understanding of autoimmune diseases. Autoimmun Rev. 2020;19(2):102450. DOI:10.1016/j.autrev.2019.102450
39. Гордеев А.В., Галушко Е.А., Насонов Е.Л. Концепция мультиморбидности в ревматологической практике. Научно-практическая ревматология. 2014;52(4):362-5 [Gordeev AV, Galushko EA, Nasonov EL. The concept of multimorbidity in rheumatologic practice. Rheumatology Science and Practice. 2014;52(4):362-5 (in Russian)].
DOI:10.14412/1995-4484-2014-362-365
40. Roy P, Orecchioni M, Ley K. How the immune system shapes atherosclerosis: roles of innate and adaptive immunity. Nat Rev Immunol. 2022;22(4):251-65.
DOI:10.1038/s41577-021-00584-1
41. Насонов Е.Л. Коронавирусная болезнь 2019 (COVID-19): размышления ревматолога. Научно-практическая ревматология. 2020;58(2):123-32 [Nasonov EL. Coronavirus disease 2019 (COVID-19): A Rheumatologist’s thoughts. Rheumatology Science and Practice. 2020;58(2):123-32 (in Russian)]. DOI:10.14412/1995-4484-2020-123-132
42. Knight JS, Caricchio R, Casanova JL, et al. The intersection of COVID-19 and autoimmunity. J Clin Invest. 2021;131(24):e154886. DOI:10.1172/JCI154886
43. Насонов Е.Л., Бекетова Т.В., Решетняк Т.М., и др. Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные ревматические заболевания: на перекрестке проблем тромбовоспаления и аутоиммунитета. Научно-практическая ревматология. 2020;58(4):353-67 [Nasonov EL, Beketova TV, Reshetnyak TM, et al. Coronavirus disease 2019 (COVID-19) and immune-mediated inflammatory rheumatic diseases: at the crossroads of thromboinflammation and autoimmunity. Rheumatology Science and Practice. 2020;58(4):353-67 (in Russian)]. DOI:10.47360/1995-4484-2020-353-367
44. Nasonov EL, Samsonov MY, Lila AM. Coronavirus Infection 2019 (COVID-19) and Autoimmunity. Her Russ Acad Sci. 2022;92(4):398-403. DOI:10.1134/S1019331622040062
45. Chang R, Yen-Ting Chen T, Wang SI, et al. Risk of autoimmune diseases in patients with COVID-19: A retrospective cohort study. EClinicalMedicine. 2023;56:101783. DOI:10.1016/j.eclinm.2022.101783
46. Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175-87. DOI:10.1136/annrheumdis-2017-211555
47. Насонов Е.Л. Фармакотерапия ревматоидного артрита: новая стратегия, новые мишени. Научно-практическая ревматология. 2017;55(4):409-19 [Nasonov EL. Pharmacotherapy for rheumatoid arthritis: new strategy, new targets. Rheumatology Science and Practice. 2017;55(4):409-19 (in Russian)]. DOI:10.14412/1995-4484-2017-409-419
48. Насонов Е.Л., Бекетова Т.В., Ананьева Л.П., и др. Перспективы анти-В-клеточной терапии при иммуновоспалительных ревматических заболеваниях. Научно-практическая ревматология. 2019;57:1-40 [Nasonov EL, Beketova TV, Ananyeva LP, et al. Prospects for anti-B-cell therapy in immuno-inflammatory rheumatic diseases. Rheumatology Science and Practice. 2019;57:1-40 (in Russian)]. DOI:10.14412/1995-4484-2019-3-40
49. Orvain C, Boulch M, Bousso P, et al. Is there a place for chimeric antigen receptor-T cells in the treatment of chronic autoimmune rheumatic diseases? Arthritis Rheumatol. 2021;73(11):1954-65. DOI:10.1002/art.41812
50. Насонов Е.Л., Лила А.М. Ингибиторы Янус-киназ при иммуновоспалительных ревматических заболеваниях: новые возможности и перспективы. Научно-практическая ревматология. 2019;57(1):8-16 [Nasonov EL, Lila AM. Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: New opportunities and prospects. Rheumatology Science and Practice. 2019;57(1):8-16 (in Russian)]. DOI:10.14412/1995-4484-2019-8-16
51. Насонов Е.Л. Абатацепт при ревматоидном артрите: новая форма, новые механизмы, новые возможности. Научно-практическая ревматология. 2015;53(5):522-41 [Nasonov EL. Abatacept for rheumatoid arthritis: a novel formulation, new mechanisms, new possibilities. Rheumatology Science and Practice. 2015;53(5):522-41 (in Russian)]. DOI:10.14412/1995-4484-2015-522-541
52. Насонов Е.Л., Решетняк Т.М., Алекберова З.С. Тромботическая микроангиопатия в ревматологии: связь тромбовоспаления и аутоиммунитета. Терапевтический архив. 2020;92(5):4-14 [Nasonov EL, Reshetnyak TM, Alekberova ZS. Thrombotic microangiopathy in rheumatology: the relationship of thrombosis and autoimmunity. Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(5):4-14 (in Russian)]. DOI:10.26442/00403660.2020.05.000697
53. Насонов Е.Л., Лила А.М., Галушко Е.А., Амирджанова В.Н. Стратегия развития ревматологии: от научных достижений к практическому здравоохранению. Научно-практическая ревматология. 2017;55(4):339-43 [Nasonov EL, Lila AM, Galushko EA, Amirdzhanova VN. Strategy for development of rheumatology: from scientific achievements to practical healthcare. Rheumatology Science and Practice. 2017;55(4):339-43 (in Russian)]. DOI:10.14412/1995-4484-2017-339-343
54. Насонов Е.Л., Александрова Е.Н., Новиков А.А. Аутоиммунные ревматические заболевания – проблемы иммунопатологии и персонифицированной терапии. Вестник РАМН. 2015;70(2):169-82 [Nasonov EL, Aleksandrova EN, Novikov AA. Autoimmune Rheumatic Diseases – Problems of Immunopathology and Personalized Treatment. Vestnik RAMN. 2015;70(2):169-82 (in Russian)]. DOI:10.15690/vramn.v70i2.1310
55. Laigle L, Chadli L, Moingeon P. Biomarker-driven development of new therapies for autoimmune diseases: current status and future promises. Expert Rev Clin Immunol. 2023;19(3):305-14. DOI:10.1080/1744666X.2023.2172404
56. Felten R, Mertz P, Sebbag E, et al. Novel therapeutic strategies for autoimmune and inflammatory rheumatic diseases. Drug Discov Today. 2023;28(7):103612. DOI:10.1016/j.drudis.2023.1
________________________________________________
2. McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med. 2006;3(8):e297. DOI:10.1371/journal.pmed.0030297
3. Szekanecz Z, McInnes IB, Schett G, et al. Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases. Nat Rev Rheumatol. 2021;17(10):585-95. DOI:10.1038/s41584-021-00652-9
4. Kerner G, Neehus AL, Philippot Q, et al. Genetic adaptation to pathogens and increased risk of inflammatory disorders in post-Neolithic Europe. Cell Genom. 2023;3(2):100248. DOI:10.1016/j.xgen.2022.100248
5. Nasonov EL. Modern concept of autoimmunity in rheumatology. Rheumatology Science and Practice. 2023;61(4):397-420 (in Russian). DOI:10.47360/1995-4484-2023-397-420
6. Bluestone JA. Mechanisms of tolerance. Immunol Rev. 2011;24(1):5-19. DOI:10.1111/j.1600-065X.2011.01019.x
7. Rosenblum MD, Remedios KA, Abbas AK. Mechanisms of human autoimmunity. J Clin Invest. 2015;125(6):2228-33. DOI:10.1172/JCI78088
8. Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015;278(4):369-95. DOI:10.1111/joim.12395
9. Pisetsky DS. Pathogenesis of autoimmune disease. Nat Rev Nephrol. 2023:1-16. DOI:10.1038/s41581-023-00720-1
10. McGonagle D, Aydin SZ, Gül A, et al. 'MHC-I-opathy'-unified concept for spondyloarthritis and Behçet disease. Nat Rev Rheumatol. 2015;11(12):731-40. DOI:10.1038/nrrheum.2015.147
11. Nasonov EL, Avdeeva AS, Dibrov DA. Rheumatoid arthritis as a clinical and immunological syndrome: focus on the seronegative subtype of the disease. Rheumatology Science and Practice. 2023;61(3):276-91 (in Russian). DOI:10.47360/1995-4484-2023-276-291
12. Lenti MV, Rossi CM, Melazzini F, et al. Seronegative autoimmune diseases: A challenging diagnosis. Autoimmun Rev. 2022;21(9):103143. DOI:10.1016/j.autrev.2022.103143
13. Schett G, McInnes IB, Neurath MF. Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs. N Engl J Med. 2021;385(7):628-39. DOI:10.1056/NEJMra1909094
14. van Wesemael TJ, Huizinga TWJ, Toes REM, an der Woude D. From phenotype to pathophysiology – placing rheumatic diseases in an immunological perspective. Lancet Rheumatol. 2022. DOI:10.1016/S2665-9913(21)00369-6
15. Bieber K, Hundt JE, Yu X, et al. Autoimmune pre-disease. Autoimmun Rev. 2023;22(2):103236. DOI:10.1016/j.autrev.2022.103236
16. Nasonov EL. Problems of rheumatoid arthritis immunopathology: evolution of the disease. Rheumatology Science and Practice. 2017;55(3):277-94 (in Russian).
DOI:10.14412/1995-4484-2017-277-294
17. Nasonov EL, Popkova TV, Panafidina TA. Problems of early diagnosis of systemic lupus erythematosus during the COVID-19 pandemic. Rheumatology Science and Practice. 2021;59(2):119-28 (in Russian). DOI:10.47360/1995-4484-2021-119-128
18. Rojas M, Ramírez-Santana C, Acosta-Ampudia Y, et al. New insights into the taxonomy of autoimmune diseases based on polyautoimmunity. J Autoimmun. 2022;126:102780. DOI:10.1016/j.jaut.2021.102780
19. Miller FW. The increasing prevalence of autoimmunity and autoimmune diseases: an urgent call to action for improved understanding, diagnosis, treatment, and prevention. Curr Opin Immunol. 2023;80:102266. DOI:10.1016/j.coi.2022.102266
20. Conrad N, Misra S, Verbakel JY, et al. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet. 2023;401(10391):1878-90. DOI:10.1016/S0140-6736(23)00457-9
21. David T, Ling SF, Barton A. Genetics of immune-mediated inflammatory diseases. Clin Exp Immunol. 2018;193(1):3-12. DOI:10.1111/cei.13101
22. Cutolo M, Straub RH. Sex steroids and autoimmune rheumatic diseases: state of the art. Nat Rev Rheumatol. 2020;16(11):628-44. DOI:10.1038/s41584-020-0503-4
23. Sundaresan B, Shirafkan F, Ripperger K, Rattay K. The Role of Viral Infections in the Onset of Autoimmune Diseases. Viruses. 2023;15(3):782. DOI:10.3390/v15030782
24. Hahn J, Cool NR, Alexander EK, et al. Vitamin d and marine 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial. BMJ. 2022;376:e066452/bmj-2021-066452. DOI:10.1136/bmj-2021-066452
25. Shaheen WA, Quraishi MN, Iqbal TH. Gut microbiome and autoimmune disorders. Clin Exp Immunol. 2022;209(2):161-74. DOI:10.1093/cei/uxac057
26. Chaturvedi S, Braunstein EM, Brodsky RA. Antiphospholipid syndrome: Complement activation, complement gene mutations, and therapeutic implications. J Thromb Haemost. 2021;19(3):607-16. DOI:10.1111/jth.15082
27. Rubin SJS, Bloom MS, Robinson WH. B cell checkpoints in autoimmune rheumatic diseases. Nat Rev Rheumatol. 2019;15(5):303-15. DOI:10.1038/s41584-019-0211-0
28. Jenks SA, Cashman KS, Woodruff MC, et al. Extrafollicular responses in humans and SLE. Immunol Rev. 2019;288(1):136-48. DOI:10.1111/imr.12741
29. Nasonov EL, Popkova TV, Lila AM. Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice. Rheumatology Science and Practice. 2021;59(4):367-83 (in Russian). DOI:10.47360/1995-4484-2021-367-383
30. Annunziato F, Romagnani C, Romagnani S. The 3 major types of innate and adaptive cell-mediated effector immunity. J Allergy Clin Immunol. 2015;135(3):626-35. DOI:10.1016/j.jaci.2014.11.001
31. Vorobyova NV, Chernyak BV. NETosis: molecular mechanisms, role in physiology and pathology. Biochemistry. 2020;85:1383-97 (in Russian). DOI:10.31857/S0320972520100061
32. Wigerblad G, Kaplan MJ. Neutrophil extracellular traps in systemic autoimmune and autoinflammatory diseases. Nat Rev Immunol. 2023;23(5):274-88.
DOI:10.1038/s41577-022-00787-0
33. Nasonov EL, Avdeeva AS. Immunoinflammatory rheumatic diseases associated with type i interferon: new evidence. Rheumatology Science and Practice. 2019;57(4):452-61 (in Russian). DOI:10.14412/1995-4484-2019-452-461
34. Nasonov EL, Avdeeva AS, Popkova TV. New possibilities of pharmacotherapy for systemic lupus erythematosus: Prospects for the use of anifrolumab (monoclonal antibodies to type I interferon receptor). Rheumatology Science and Practice. 2021;59(5):537-46 (in Russian). DOI:10.47360/1995-4484-2021-537-546
35. Suurmond J, Diamond B. Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity. J Clin Invest. 2015;125(6):2194-202. DOI:10.1172/JCI78084
36. Burbelo PD, Iadarola MJ, Keller JM, Warner BM. Autoantibodies Targeting Intracellular and Extracellular Proteins in Autoimmunity. Front Immunol. 2021;12:548469. DOI:10.3389/fimmu.2021.548469
37. Sokolova MV, Schett G, Steffen U. Autoantibodies in Rheumatoid Arthritis: Historical Background and Novel Findings. Clin Rev Allergy Immunol. 2022;63(2):138-51. DOI:10.1007/s12016-021-08890-1
38. Moritz CP, Paul S, Stoevesandt O, et al. Autoantigenomics: Holistic characterization of autoantigen repertoires for a better understanding of autoimmune diseases. Autoimmun Rev. 2020;19(2):102450. DOI:10.1016/j.autrev.2019.102450
39. Gordeev AV, Galushko EA, Nasonov EL. The concept of multimorbidity in rheumatologic practice. Rheumatology Science and Practice. 2014;52(4):362-5 (in Russian). DOI:10.14412/1995-4484-2014-362-365
40. Roy P, Orecchioni M, Ley K. How the immune system shapes atherosclerosis: roles of innate and adaptive immunity. Nat Rev Immunol. 2022;22(4):251-65.
DOI:10.1038/s41577-021-00584-1
41. Nasonov EL. Coronavirus disease 2019 (COVID-19): A Rheumatologist’s thoughts. Rheumatology Science and Practice. 2020;58(2):123-32 (in Russian).
DOI:10.14412/1995-4484-2020-123-132
42. Knight JS, Caricchio R, Casanova JL, et al. The intersection of COVID-19 and autoimmunity. J Clin Invest. 2021;131(24):e154886. DOI:10.1172/JCI154886
43. Nasonov EL, Beketova TV, Reshetnyak TM, et al. Coronavirus disease 2019 (COVID-19) and immune-mediated inflammatory rheumatic diseases: at the crossroads of thromboinflammation and autoimmunity. Rheumatology Science and Practice. 2020;58(4):353-67 (in Russian). DOI:10.47360/1995-4484-2020-353-367
44. Nasonov EL, Samsonov MY, Lila AM. Coronavirus Infection 2019 (COVID-19) and Autoimmunity. Her Russ Acad Sci. 2022;92(4):398-403. DOI:10.1134/S1019331622040062
45. Chang R, Yen-Ting Chen T, Wang SI, et al. Risk of autoimmune diseases in patients with COVID-19: A retrospective cohort study. EClinicalMedicine. 2023;56:101783. DOI:10.1016/j.eclinm.2022.101783
46. Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175-87. DOI:10.1136/annrheumdis-2017-211555
47. Nasonov EL. Pharmacotherapy for rheumatoid arthritis: new strategy, new targets. Rheumatology Science and Practice. 2017;55(4):409-19 (in Russian).
DOI:10.14412/1995-4484-2017-409-419
48. Nasonov EL, Beketova TV, Ananyeva LP, et al. Prospects for anti-B-cell therapy in immuno-inflammatory rheumatic diseases. Rheumatology Science and Practice. 2019;57:1-40 (in Russian). DOI:10.14412/1995-4484-2019-3-40
49. Orvain C, Boulch M, Bousso P, et al. Is there a place for chimeric antigen receptor-T cells in the treatment of chronic autoimmune rheumatic diseases? Arthritis Rheumatol. 2021;73(11):1954-65. DOI:10.1002/art.41812
50. Nasonov EL, Lila AM. Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: New opportunities and prospects. Rheumatology Science and Practice. 2019;57(1):8-16 (in Russian). DOI:10.14412/1995-4484-2019-8-16
51. Nasonov EL. Abatacept for rheumatoid arthritis: a novel formulation, new mechanisms, new possibilities. Rheumatology Science and Practice. 2015;53(5):522-41 (in Russian). DOI:10.14412/1995-4484-2015-522-541
52. Nasonov EL, Reshetnyak TM, Alekberova ZS. Thrombotic microangiopathy in rheumatology: the relationship of thrombosis and autoimmunity. Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(5):4-14 (in Russian). DOI:10.26442/00403660.2020.05.000697
53. Nasonov EL, Lila AM, Galushko EA, Amirdzhanova VN. Strategy for development of rheumatology: from scientific achievements to practical healthcare. Rheumatology Science and Practice. 2017;55(4):339-43 (in Russian). DOI:10.14412/1995-4484-2017-339-343
54. Nasonov EL, Aleksandrova EN, Novikov AA. Autoimmune Rheumatic Diseases – Problems of Immunopathology and Personalized Treatment. Vestnik RAMN. 2015;70(2):169-82 (in Russian). DOI:10.15690/vramn.v70i2.1310
55. Laigle L, Chadli L, Moingeon P. Biomarker-driven development of new therapies for autoimmune diseases: current status and future promises. Expert Rev Clin Immunol. 2023;19(3):305-14. DOI:10.1080/1744666X.2023.2172404
56. Felten R, Mertz P, Sebbag E, et al. Novel therapeutic strategies for autoimmune and inflammatory rheumatic diseases. Drug Discov Today. 2023;28(7):103612. DOI:10.1016/j.drudis.2023.1
Авторы
Е.Л. Насонов*
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», Москва, Россия;
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия
*nasonov@irramn.ru
Nasonova Research Institute of Rheumatology, Moscow, Russia;
Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
*nasonov@irramn.ru
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», Москва, Россия;
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия
*nasonov@irramn.ru
________________________________________________
Nasonova Research Institute of Rheumatology, Moscow, Russia;
Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
*nasonov@irramn.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.